Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Immunovaccine`s Patented DepoVax Technology




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Immunovaccine`s Patented DepoVax Technology
Released on: December 01, 2010. © PharmaTelevision Ltd
Visitors: You are watching a 5 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Vicki L. Morgan MBA, Director of Business Development, ImmunoVaccine Inc. They discuss:

• Origins of Immunovaccine

• Depovax Technology of Immunovaccine

• Partnership Strategy of Immunovaccine in terms of developing product

• Deal with Merck

• The Depovax challenge program

• Future plans
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Origins of Immunovaccine
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston. On this show I have Vicki L. Morgan , who is Business Development Director at a company called Immunovaccine Inc based in Halifax, Canada, welcome to the show.
Vicki L. Morgan:
Thank you for having me.
Fintan Walton:
Vicki , tell us a little bit about the origins of Immunovaccine Inc ?
Vicki L. Morgan:
Immunovaccine came out of Dalhousie University in the Halifax area back in 2000 we originally started as an animal health company, but today we develop premium vaccinesfor human health and specifically the areas of therapeuticcancer and infectious diseases.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Vicki L Morgan
Director
Vicki L. Morgan is currently Director, Business Development at Immunovaccine Inc based in Halifax, Canada. Vicki L. Morgan has more than 15 years leading business development and partnership initiatives across various sized companies ranging from start-up biotechnology to Fortune 200. She joined New Perspectives Inc to focus on new company formation; specifically providing leadership, business strategy, business development and licensing expertise to emerging companies involved in the life sciences. Additionally, New Perspectives Inc works with current biotechnology and medical device companies to support business development & licensing activities and strategic collaborations with scientists and inventors from Universities and private Technology Centers. Most recently she held a position with Nektar Therapeutics as Director of Business Development responsible for licensing activities of Nektar Therapeutics's proprietary products in gastroenterology, pain and oncology therapeutics. Prior to Nektar Therapeutics, Vicki worked with Kimberly-Clark Corporation in the Global Alliances and Technology Acquisition group leading and managing strategic partnerships and alliances across all sectors of Kimberly-Clark Corporation including Health Care, Consumer Products, Professional Products and Innovation and Emerging Growth divisions. In 2000, Vicki joined Nobex Corporation, a drug delivery company focused in the application of medicinal and polymer chemistry to the challenges of drug delivery, to lead the marketing and business development activities. Vicki L. Morgan 's entrepreneurial experience started early in her career as she spent several years directing business development, sales and marketing efforts in a nutrition and wellness-focused company she co-founded, Worldwide Zone. She began her career with Alsace International, a regional government development group in Strasbourg, France promoting biotechnology industry collaborations in North America. Vicki L. Morgan is a member of the Licensing Executives Society and served on the Advisory Board of Envion International. Vicki L. Morgan 's Specialties: A Business Development and Marketing professional with more than 15 years of success initiating and building productive collaborations and partnerships with biotechnology, pharmaceutical, and consumer health care companies. Specialized in establishing and executing partnering strategy, term sheet development, contract negotiation, and coordinating teams for due diligence. She had done her graduation from Miami University.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Immunovaccine Inc
Immunovaccine Inc (TSX-V: IMV) is focused on the commercialization of its patented vaccine delivery and enhancement technology, the DepoVax platform that boasts such benefits as enhanced efficacy with fewer doses. Positive pre-clinical safety and efficacy data generated by the DepoVax platform has attracted multiple partnerships. Immunovaccine Inc has also signed four licensing deals with Pfizer Animal Health and generated early revenues as a result. The Company's focus on developing human health vaccines has led to the in-licensing of Survivac from Merck KGaA. Survivac is a novel cancervaccine which targets multiple Survivin-expressing solid tumors. Immunovaccine Inc has exclusive, worldwide rights to develop and commercialize the Survivin-based vaccineand plans to formulate it in the DepoVax delivery platform. Taking the DPX-Survivac into an accelerated clinical program is a priority for the Company because of its broad market potential and its potential utility in several cancer indications. The National Cancer Institute (NCI) has ranked Survivin among the world's top 25 most promising antigens. Immunovaccine Inc 's aggressive growth strategy is led by an experienced management and board, consisting of former senior executives of Sanofi and a member of the Canadian Medical Hall of Fame. The Company is currently midway through a phase I clinical trial for DPX-0907, a therapeuticvaccine based on the DepoVax technology. Through its own biotech research and collaborations with partners, Immunovaccine Inc has been honoured as one of Canada's Top 10 Life Sciences Companies. Today, the company is advancing DepoVax based vaccines in a variety of indications that range from cancer to autoimmune disease through its own pipeline and a number of strategic collaborations and alliances around the world.